1 July 2025 MBS Pathology Changes

This page provides information on the 1 July 2025 changes to MBS pathology items.

Page last updated: 30 June 2025

Effective 1 July 2025, the following amended pathology items will be listed on the Medicare Benefits Schedule (MBS):

    • Amendments to MBS for urine testing in asymptomatic patients (MBS item 69333)
    • Amendments to MBS for Vitamin B12 testing (item 69838, 69839 and new item 66842)
    • Items under MBS pathology service groups Haematology (P1), Immunology (P4), Tissue Pathology (P5), Cytology (P6) and Infertility & Pregnancy (P8) will have their fees indexed annually.
    • A new item will be listed on the MBS for isocitrate dehydrogenase 1 (IDH1) variant testing in patients with cholangiocarcinoma (CCA) to determine eligibility for a relevant treatment on the Pharmaceutical Benefits Scheme (PBS)

Further information is provided in the factsheets below:

Factsheet
PDF and Word versions
Amendments to MBS for urine testing in asymptomatic patients
(Last updated:
 3 June 2025)
Amendments to MBS for Vitamin B12 testing
(Last updated: 
3 June 2025)
Introduction of annual indexation for certain pathology services
(Last updated: 
19 May 2025)
New MBS item for IDH1 variant testing in patients with CCA
(Last updated: 30 June 2025)


    In this section